论文部分内容阅读
目的观察左卡尼汀治疗不稳定型心绞痛患者的临床疗效和安全性。方法将72例同期收治的不稳定型心绞痛患者随机分为治疗组(39例)和对照组(33例),两组患者年龄、性别、病情等方面比较差异无统计学意义(P>0.05)。对照组常规应用硝酸酯类、β-受体阻滞剂、肠溶阿司匹林、钙拮抗剂、低分子肝素等药物治疗,治疗组在此基础上加用左卡尼汀3.0 g静脉滴注,每日1次,治疗2～3周。观察治疗组和对照组心绞痛严重程度分级改善率、心绞痛症状改善率、每日心绞痛发作次数、硝酸甘油每日用量。结果 3周后,治疗组心绞痛严重程度分级改善率、症状改善显效率高于对照组(P<0.05),硝酸甘油的每日用量低于对照组(P<0.05),但每日心绞痛发作次数差异不具统计学意义,无不良反应发生。结论左卡尼汀用于治疗不稳定型心绞痛疗效安全肯定。
Objective To observe the clinical efficacy and safety of levocarnitine in patients with unstable angina pectoris. Methods Seventy-two patients with unstable angina pectoris treated at the same period were randomly divided into treatment group (n = 39) and control group (n = 33). There was no significant difference in age, sex and disease between the two groups (P> 0.05) . The control group routinely used nitrates, β-blockers, enteric-coated aspirin, calcium antagonists, low molecular weight heparin and other drugs on the basis of the treatment group with levocarnitine 3.0 g intravenous infusion, each Day 1, treatment 2 to 3 weeks. The severity of angina pectoris, the rate of improvement of angina pectoris, the number of daily angina pectoris and the daily dosage of nitroglycerin were observed in the treatment group and the control group. Results After 3 weeks, the improvement rate of angina pectoris severity and the improvement of symptoms in treatment group were higher than those in control group (P <0.05). The daily dose of nitroglycerin was lower than that of control group (P <0.05), but the number of daily angina pectoris The difference was not statistically significant, no adverse reactions occurred. Conclusion The efficacy of levocarnitine in the treatment of unstable angina pectoris is surely safe.